Jeffrey Bluestone A.'s most recent trade in Gilead Sciences, Inc. was a trade of 5,000 Common Stock done at an average price of $67.5 . Disclosure was reported to the exchange on July 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 67.45 per share. | 14 Jul 2025 | 5,000 | 13,920 (0%) | 0% | 67.5 | 337,250 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2025 | 5,000 | 9,665 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Sale of securities on an exchange or to another person at price $ 109.74 per share. | 14 Jul 2025 | 5,000 | 8,920 (0%) | 0% | 109.7 | 548,700 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 6,809 | 6,809 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 1,516 | 5,713 | - | - | Restricted Stock Unit | |
| Gilead Sciences | A. Bluestone Jeffrey | Director | Sale of securities on an exchange or to another person at price $ 91.39 per share. | 26 Nov 2024 | 6,788 | 8,920 (0%) | 0% | 91.4 | 620,356 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2024 | 5,879 | 0 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey Bluestone A. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.17 per share. | 26 Nov 2024 | 5,879 | 11,587 (0%) | 0% | 61.2 | 359,618 | Common Stock |
| Gilead Sciences | Bluestone A. Jeffrey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2024 | 4,121 | 11,730 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | A. Bluestone Jeffrey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 61.35 per share. | 26 Nov 2024 | 4,121 | 15,708 (0%) | 0% | 61.3 | 252,823 | Common Stock |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 12,648 | 12,648 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 2,310 | 4,197 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 10,173 | 10,173 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 May 2023 | 1,887 | 1,887 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 15,851 | 15,851 | - | - | Non-qualified Stock Option (Right to Buy) | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2022 | 2,444 | 5,708 (0%) | 0% | 0 | Common Stock | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 0 | - | - | Restricted Stock Unit | |
| Gilead Sciences | Jeffrey A. Bluestone | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2022 | 2,223 | 3,264 (0%) | 0% | - | Common Stock |